At present, 20-30% of detected breast cancers are ductal carcinoma in situ (DCIS). Adjuvant therapy after complete surgical excision of DCIS can reduce local recurrence rates but probably has no effect on survival for most patients. The principal aim in DCIS management is prevention of invasive disease.
展开▼
